Curis Inc., a biotechnology company specializing in the development of emavusertib, reported its financial results for the second quarter of 2025. The company posted a net loss of $8.6 million, or $0.68 per share, compared to a net loss of $11.8 million, or $2.03 per share, in the same period in 2024. For the first half of 2025, Curis recorded a net loss of $19.2 million, or $1.82 per share, compared to a net loss of $23.7 million, or $4.08 per share, for the corresponding period in 2024. Revenues for the second quarter increased to $2.7 million from $2.5 million in the same quarter of the previous year. For the six months ending June 30, 2025, revenues reached $5.1 million, up from $4.6 million in the first half of 2024. These revenues were derived from royalty revenues from Genentech/Roche's sales of Erivedge®. Research and development expenses decreased to $7.5 million in the second quarter of 2025 from $10.3 million during the same period in 2024, largely due to reduced employee-related, research, consulting, and clinical costs. For the first half of 2025, these expenses totaled $16.0 million, down from $19.9 million in 2024. Curis ended the second quarter of 2025 with $10.1 million in cash and cash equivalents, and approximately 10.7 million shares of common stock outstanding. The company anticipates that its current cash, along with $6.0 million in net proceeds from the July 2025 offerings, will sustain its operations into the first quarter of 2026. Additionally, Curis announced that additional data from the TakeAim Lymphoma study is expected later this year.